Using the Affymetrix 500K Mapping array and publicly available genotypes, we identified 18 SNPs whose allele frequency differed significantly(P o 1 Â 10 À5 ) between pediatric acute lymphoblastic leukemia (ALL) cases (n ¼ 317) and non-ALL controls (n ¼ 17,958). Two SNPs in ARID5B not only differed between ALL and non-ALL groups (rs10821936, P ¼ 1.4 Â 10 À15 , odds ratio (OR) ¼ 1.91; rs10994982, P ¼ 5.7 Â 10 À9 , OR ¼ 1.62) but also distinguished B-hyperdiploid ALL from other subtypes (rs10821936, P ¼ 1.62 Â 10 À5 , OR ¼ 2.17; rs10994982, P ¼ 0.003, OR 1.72). These ARID5B SNPs also distinguished B-hyperdiploid ALL from other subtypes in an independent validation cohort (n ¼ 124 children with ALL; P ¼ 0.003 and P ¼ 0.0008, OR 2.45 and 2.86, respectively) and were associated with methotrexate accumulation and gene expression pattern in leukemic lymphoblasts. We conclude that germline variants affect susceptibility to, and characteristics of, specific ALL subtypes.
Using the Affymetrix 500K Mapping array and publicly available genotypes, we identified 18 SNPs whose allele frequency differed significantly(P o 1 Â 10 À5 ) between pediatric acute lymphoblastic leukemia (ALL) cases (n ¼ 317) and non-ALL controls (n ¼ 17,958). Two SNPs in ARID5B not only differed between ALL and non-ALL groups (rs10821936, P ¼ 1.4 Â 10 À15 , odds ratio (OR) ¼ 1.91; rs10994982, P ¼ 5.7 Â 10 À9 , OR ¼ 1.62) but also distinguished B-hyperdiploid ALL from other subtypes (rs10821936, P ¼ 1.62 Â 10 À5 , OR ¼ 2.17; rs10994982, P ¼ 0.003, OR 1.72). These ARID5B SNPs also distinguished B-hyperdiploid ALL from other subtypes in an independent validation cohort (n ¼ 124 children with ALL; P ¼ 0.003 and P ¼ 0.0008, OR 2.45 and 2.86, respectively) and were associated with methotrexate accumulation and gene expression pattern in leukemic lymphoblasts. We conclude that germline variants affect susceptibility to, and characteristics of, specific ALL subtypes.
Pediatric ALL comprises biologically and clinically diverse subtypes. Somatically acquired genetic aberrations in ALL lymphoblasts are prognostic and can guide risk-directed therapy 1 . However, the extent to which germline variation contributes to ALL susceptibility, to the acquisition of genetic aberrations that define ALL subtypes and to the response to drug therapy among subtypes is unknown. Candidate gene approaches have identified inherited polymorphisms in loci that may contribute to ALL susceptibility, including the multidrug resistance gene ABCB1 (also called MDR1) and the genes for methylenetetrahydrofolate reductase (MTHFR) and the glutathione-S-transferases, as well as cell cycle inhibitor and DNA mismatch repair genes 2-7 . Lacking, however, are genome-wide studies that assess how inherited variation contributes to the development of ALL. Therefore, we conducted a genome-wide association study in children with newly diagnosed ALL to identify germline SNPs that may be associated with the development of ALL and with specific ALL subtypes.
We first identified SNPs whose allele frequency differed between a discovery cohort of 317 children of European descent with ALL and 17,958 individuals of European descent without ALL from three independent control groups (see Online Methods and Supplementary  Fig. 1 ). After applying quality control criteria, we evaluated 307,944 germline SNPs. Eighteen SNPs differed significantly in allele frequency (using P-value thresholds specified in Supplementary Fig. 1 ) between children with ALL and unaffected controls ( Table 1 and Fig. 1) ; the 18 SNPs were annotated to 12 unique genes, with odds ratios ranging from 1.43 to 3.62. Two of the SNPs were annotated to the AT-rich interactive domain 5B (ARID5B) gene annotated to chromosomal region 10q11.22 (rs10821936, P ¼ 1.4 Â 10 À15 ; rs10994982, P ¼ 5.7 Â 10 À9 ) and were in linkage disequilibrium (LD) with one another (r 2 ¼ 0.42, P o 1 Â 10 À10 ). Three SNPs were annotated to chromosomal region 7p12.2-one to the zinc finger protein subfamily 1A (IKZF1) gene (rs11978267, P ¼ 8.8x10 À11 ) and the other two to the dopa decarboxylase aromatic L-amino acid (DDC) gene (rs2167364, P ¼ 2.8 Â 10 À6 and rs2242041, P ¼ 9.9 Â 10 À7 ). These three SNPs were in LD with each other (pairwise r 2 4 0.28, P o 1 Â 10 À10 ).
We next compared the allele frequency of these 18 SNPs among the four most common, non-overlapping ALL subtypes (B-other, B-hyperdiploid, t(12;21)/ETV6-RUNX1 and T-cell ALL) in the discovery cohort and found that six SNPs distinguished among the subtypes (P r 0.05) ( Table 2 ). The two ARID5B SNPs (rs10821936 and rs10994982) distinguished B-hyperdiploid ALL from the other three subtypes: for example, the frequency of the C allele at rs10821936 was greater in individuals with B-hyperdiploid ALL (61%) than in all other ALL cases combined (42%; P ¼ 1.62 Â 10 À5 ) and than in non-ALL controls (33%) (Tables 2 and 3). The three SNPs localized to 7p12.2 distinguished T-cell ALL from the three other subtypes (P r 0.020). One SNP annotated to OR2C3 was associated with the t(12;21)/ETV6-RUNX1 subtype (P ¼ 0.021).
Two of the six SNPs that distinguished ALL subtypes in the discovery cohort also distinguished subtypes in a validation cohort of children of European descent with ALL (n ¼ 124). Both SNPs were annotated to ARID5B, both distinguished B-hyperdiploid ALL from other subtypes (Tables 2 and 3 ) and both were confirmed with an alternative genotyping methodology with 499% accuracy (see Online Methods). A haplotype analysis in the combined ALL cohort (discovery plus validation cohorts) revealed that haplotypes including both ARID5B SNPs distinguished cases with B-hyperdiploid ALL from other ALL cases (score test P ¼ 1.0 Â 10 À6 ; Supplementary Table 1) . The allele frequencies of the other four SNPs (Table 2) were not significantly different among the four ALL subtypes in the validation cohort after correction for multiple testing, although some SNPs (such as rs2167364, P ¼ 0.03) showed a statistical trend toward subtype association.
The ARID5B SNPs were associated with B-hyperdiploid ALL, which has a better response to methotrexate chemotherapy than other ALL subtypes 8 . Because this response is partly due to greater accumulation of methotrexate polyglutamates in B-hyperdiploid than in non-B-hyperdiploid ALL blast cells 9 , we investigated whether these SNPs were associated with the clinical phenotype of methotrexate polyglutamate accumulation. We found the same alleles of ARID5B SNPs (rs10821936 and rs10994982) that were associated with B-hyperdiploid ALL were also associated with greater methotrexate polyglutamate accumulation (P ¼ 0.005 and P ¼ 0.021, respectively) in individuals with this ALL subtype (n ¼ 37; Supplementary Fig. 2 ). Both SNPs were also associated with the expression phenotype of global gene expression pattern in B-hyperdiploid ALL blast cells (n ¼ 44, Supplementary Fig. 3 ). The expression of eight genes was associated with ARID5B SNP genotype (P o 5.3 Â 10 À5 , false discovery rate r10%, Supplementary Table 2 ). Of these, the MKL1 gene, which encodes the megakaryoblastic leukemia 1 protein, was most strongly associated with the ARID5B SNP genotypes (P ¼ 1.84 Â 10 À6 ). Similar associations were not observed in the other ALL subtypes.
Cancer subtype-specific genomic variation has been shown to be important in breast 10 , lung 11 , gastric 12 and myeloproliferative 13 cancers. Our study represents the first genome-wide interrogation to identify genetic risk factors for ALL, the most common childhood cancer. Because childhood ALL is a biologically heterogeneous disease with molecular subtypes that differ in response to chemotherapy and prognosis 14 , we used a genome-wide analysis to identify risk factors not only for ALL but also for the most common ALL subtypes.
Epidemiological studies have identified putative environmental 14 and genetic 15 risk factors for ALL, although most show only a modest association with disease risk, and few studies have examined specific ALL subtypes. Only a small percentage of ALL cases are associated with mendelian diseases and genetic syndromes such as Down syndrome, ataxia-telangiectasia and b-thalassemia [16] [17] [18] . The greater NA, not applicable (odds ratio could not be estimated).
a Asterisk denotes the B allele ('risk allele'), which had a higher frequency in children with ALL than in the non-ALL control groups. b Odds ratio for the likelihood of ALL among individuals carrying an additional copy of the B allele (versus A allele) at each SNP listed. For example, individuals carrying an additional copy of the B allele (encoding cytosine) at the rs10821936 SNP locus were 1.91 times as likely as others to belong to the ALL group. 95% confidence intervals are shown in parenthesis. c Odds ratio for the risk of ALL between the specified genotypes. d Logistic regression analysis comparing allele frequency at the listed SNP locus between children with ALL in the discovery cohort (n ¼ 317) and the combined non-ALL control group (n ¼ 17,958) and between children with ALL in the discovery cohort and each of the non-ALL control groups: the WTCCC group (n ¼ 14,311) and the schizophrenia (schiz.) (n ¼ 2,601) and bipolar (n ¼ 1,046) study groups from the Genetic Association Informative Network. e The allele frequency shown is listed for the B allele for each polymorphism in each population. In parentheses, the P value indicating the deviation of the observed allele frequencies for the discovery ALL population compared to that expected based on Hardy-Weinberg equilibrium is shown.
Figure 1 Genome-wide P values comparing allele frequency of SNPs between the ALL and combined non-ALL groups according to chromosome. The x axis shows the P values (-log 10 ) for 307,944 germline SNPs. The allele frequency of the SNPs was compared between children with ALL in the discovery cohort (n ¼ 317) and the combined non-ALL control cohort (n ¼ 17,958). The SNP whose allele frequency differed most significantly between the two cohorts (P ¼ 1.4 Â 10 À15 ) was localized to chromosome 10. The dashed line shows the threshold P value indicating genomewide significance.
risk of ALL in children than in adults has been linked to developmental immaturity of the immune system 19 and differential exposure to environmental toxins 20 . Because children have less cumulative exposure to mutagens than adults, some researchers hypothesize that genetic predisposition to cancer may be greater in children than in adults. Candidate gene approaches have identified polymorphisms in the carcinogen metabolism genes GSTM1, GSTT1 and CYP1A1 (ref. 21) , as well as in the cell cycle checkpoint genes CDKN1B, CDKN2A and CDKN2B (ref. 6) ( Supplementary Table 3) , that may predispose to ALL. Polymorphisms in the MTHFR and NQO1 genes have also been associated with distinct subtypes of childhood leukemia (B-hyperdiploid ALL and leukemias with MLL rearrangements, respectively) 4 . Several of these candidate genes were interrogated in our analysis. Although we acknowledge the limitations of our genotyping platforms, as well as differences in the study cohorts used, we did not find that variants in previously reported genes were associated with the risk of ALL in our study (Supplementary Table 3 ).
We used a two-step genome-wide approach to identify associations between gene polymorphisms and the risk of specific subtypes of ALL. We found 18 germline SNPs whose allele frequency differed between children of European descent with ALL and three independent European and European-American control groups ( Table 1) . We confirmed that comparing SNP data from externally genotyped controls to those from children with ALL typed at our center was unlikely to be biased by underlying population stratification (quantilequantile (Q-Q) plot, genomic control lambda parameter ¼ 1; Supplementary Fig. 4 ). Of these 18 SNPs, we tested for differences in allele frequency among the most common ALL subtypes. By using the initial case-control study as a screen, we were able to narrow our attention to polymorphisms that not only distinguished subtypes but that also might contribute to the overall risk of ALL. This two-step approach also allowed us to capture additional SNPs that might have been overlooked had we limited our analysis to subtype-related differences in SNP genotypes solely within the 317 children with ALL (Supplementary Tables 4-7) . */*, homozygous genotype for the subtype-associated allele; */-,heterozygous genotype for the subtype-associated allele; À/À homozygous genotype for the non-subtype-associated allele. NA, odds ratio cannot be estimated.
a Asterisks denote the allele associated with the indicated ALL subtype. For example, the C allele at the rs10821936 polymorphism is associated with B-hyperdiploid ALL; the A allele at the rs11978267 polymorphism is associated with T-cell ALL. b Multinomial log linear comparison of the allele frequency of each SNP among the four ALL subtypes in the discovery cohort. c Frequency of the B allele within each ALL subtype in the discovery and validation (in parentheses) cohorts. The 'non-ALL control' frequency is the mean value from the three non-ALL control groups. d The ALL subtype most strongly distinguished by the indicated polymorphism. e Odds ratio for the indicated ALL subtype versus all other subtypes among individuals carrying an additional copy of the subtype-associated allele (marked with asterisk) in the discovery and validation (in parentheses) cohorts. For example, individuals carrying an additional copy of the C allele at the rs10821936 polymorphism are 2.17 times more likely to have B-hyperdiploid ALL than all other ALL subtypes. 95% confidence intervals are shown. f Logistic regression analysis comparing allele frequency of the listed polymorphism in the indicated ALL subtype versus all other ALL subtypes combined. Polymorphisms listed in bold were significantly associated with the indicated ALL subtype in both the discovery and validation groups (in parentheses) after correction for multiple testing. g Odds ratio for the indicated ALL subtype in study subjects with the specified genotypes in discovery and validation (in parentheses) groups. Two ARID5B SNPs (rs10821936 and rs10994982; Table 2 ) discriminated B-hyperdiploid ALL from non-ALL controls and the three other major ALL subtypes. These SNPs also showed significant association with two phenotypes in B-hyperdiploid ALL: the clinical phenotype of intracellular accumulation of methotrexate polyglutamates ( Supplementary Fig. 2 ) and the expression phenotype of global gene expression pattern in ALL blast cells (Supplementary Fig. 3 ).
Both of these SNPs are located in intron 3 of the ARID5B gene and are contained within an LD block that spans exons 3 and 4 ( Supplementary Fig. 5 ). To determine whether they might exert a functional effect in ARID5B via LD with coding polymorphisms in ARID5B, we sequenced exons 3 and 4 in 63 HapMap CEPH cell lines. However, we did not identify any coding SNPs in these regions. We acknowledge that further functional analyses are required to elucidate the mechanism by which these two SNPs affect the risk of ALL.
The ARID5B gene (also known as DESRT and MRF2) encodes a member of the ARID family of transcription factors and is important in embryonic development, cell type-specific gene expression and cell growth regulation 22 . Homozygous knockout mice (Arid5b À/À ) have abnormal thymic and splenic architecture and disrupted B cell differentiation [23] [24] [25] . ARID5B expression is upregulated in individuals with acute megakaryoblastic leukemia 26 and acute promyelocytic leukemia 27 . Thus, it is possible that germline variation at the ARID5B locus affects susceptibility to this B-lineage leukemia by altering ARID5B function in B-lineage development.
Three of the 18 SNPs associated with ALL (Table 1) , localized to the genes IKZF1 and DDC in the 7p12.2 chromosomal region, distinguished T-cell from B-lineage ALL in our discovery cohort. IKZF1 encodes Ikaros, which is critical for normal mouse and human lymphoid development 28, 29 and whose deletion contributes to the pathogenesis of a very aggressive form of childhood ALL [30] [31] [32] [33] . However, the association of germline IKZF1 and DDC SNPs with T-cell ALL was not replicated in our validation cohort, possibly due to the smaller number of cases.
Our findings indicate that inherited genetic variation contributes to the risk of childhood ALL and is likely to contribute to the development of some specific ALL subtypes. The data further suggest that the same genetic variation that predisposes to B-hyperdiploid ALL may underlie the superior response of this subtype to chemotherapy. Thus, genomic variation may affect not only disease risk but treatment outcome as well.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. NCBI GEO: microarray datasets analyzed in this paper are deposited under the accession code GSE17195.
Note: Supplementary information is available on the Nature Genetics website. (R01 MH67257,  R01 MH59588, R01 MH59571, R01 MH59565, R01 MH59587, R01 MH60870,  R01 MH59566, R01 MH59586, R01 MH61675, R01 MH60879, R01 MH81800,  U01 MH46276, U01 MH46289 U01 MH46318, U01 MH79469 , and U01 MH79470) and the genotyping of samples was provided through the Genetic Association Information Network (GAIN). The datasets used for the analyses described in this manuscript were obtained from the database of Genotype and Phenotype database (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP (accession number phs000021.v1.p1). Samples and associated phenotype data for the Genome-Wide Association of Schizophrenia Study were provided by the Molecular Genetics of Schizophrenia Collaboration (Principal Investigator: P.V. Gejman, Evanston Northwestern Healthcare (ENH) and Northwestern University, Evanston, Illinois). Funding support for the Whole Genome Association Study of Bipolar Disorder was provided by the US National Institute of Mental Health (NIMH) and the genotyping of samples was provided through the Genetic Association Information Network (GAIN). The datasets used for the analyses described in this manuscript were obtained from dbGaP (accession number phs000017.v1.p1). Samples and associated phenotype data for the Collaborative Genomic Study of Bipolar Disorder were provided by The NIMH Genetics Initiative for Bipolar Disorder. Data and biomaterials were collected in four projects that participated in the NIMH Bipolar Disorder Genetics Initiative. From 1991 to 1998, the principal investigators and co-investigators were: Indiana University, Indianapolis, Indiana,
ONLINE METHODS
Case subjects and DNA samples. We analyzed germline DNA from 441 children of European descent with the four most common ALL subtypes. The discovery cohort consisted of 317 cases of European descent, including 262 cases from the St. Jude Children's Research Hospital Total XIIIB (1994) (1995) (1996) (1997) (1998) and XV (2000-2007) ALL protocols 34, 35 and 55 cases (all with B-precursor ALL subtypes) from the Children's Oncology Group (COG) 9906 study 36 . The validation cohort consisted of the next 124 children of European descent enrolled on the St. Jude Total XV ALL protocol. This study was approved by the St. Jude Institutional Review Board and signed informed consent was obtained from study participants, parents or guardians, as appropriate. For further details, see Supplementary Note.
External data sets. We obtained SNP allele frequency and genotype data from three groups of European descent to serve as non-ALL controls. One group comprised participants in the WTCCC (n ¼ 14,311) 37 , excluding those with bipolar disease. The other two groups were the Genetic Association Informative Network (GAIN) schizophrenia (phs000021.v1.p1; n ¼ 2,601) and bipolar disorder (phs000017.v1.p1; n ¼ 1,046) 38-40 study cohorts. Because the prevalence of adult survivors of childhood ALL is less than 1:1,000, these three groups were considered non-ALL controls.
Characterization of ALL molecular and immunophenotypic subgroups. The immunophenotyping and genotyping of leukemic lymphoblasts from St. Jude patients 34 and COG patients have been previously described 36, 41 . We analyzed only patients with the four most common, non-overlapping ALL subtypes: B-lineage ALL with no defined genetic or chromosomal abnormalities (B-other; n ¼ 121 in discovery cohort, n ¼ 44 in validation cohort), B-lineage hyperdiploid ALL with more than 50 chromosomes (B-hyperdiploid; n ¼ 108 and n ¼ 36), B-lineage ALL bearing the t(12;21)/ETV6-RUNX1 fusion (n ¼ 45 and n ¼ 20) and T-cell ALL (n ¼ 43 and n ¼ 24) (Supplementary Table 8 ).
Genotyping and SNP filtering criteria. DNA was extracted from the blood of children with ALL during complete remission. For children in the discovery cohort and for 65 children in the validation cohort, 500 ng of DNA was digested with NspI and StyI restriction enzymes for the 500K Array Set chips (Affymetrix). DNA was amplified, labeled and hybridized to chips as described in ref. 30 . The chips were scanned, and genotype calls were made by using the Bayesian Robust Linear Multichip with Mahalanobis Distance (BRLMM) algorithm for a total of 500,568 possible SNPs interrogated. Genotyping for 59 cases in the validation cohort was performed using the Affymetrix GenomeWide Human SNP Array 6.0 based on the Birdseed genotype-calling algorithm, which overlaps with 482,251 of the 500,568 SNPs on the 500K chip. Visual inspection of original allele-specific signal intensity plots (theta plots) was carried out to ensure that genotyping calls clustered distinctly. Genotyping for participants in the WTCCC study was performed as reported, using the Affymetrix 500K Mapping Array sets 37 . The GAIN participants were analyzed using the Affymetrix Genome-Wide Human SNP Array 6.0. The confirmation of ARID5B SNP genotypes in 386 ALL cases was performed using iPLEX from Sequenom, Inc., in the University of Chicago's Genetic Services Laboratories.
SNPs with a genotyping call rate o96% (n ¼ 84,032) in both the St. Jude and COG data sets were excluded in the discovery cohort. Of the remaining 416,536 SNPs interrogated, only those with adequate quality control measures in the WTCCC cohort 37 and both GAIN cohorts were included in the genomewide association analysis (n ¼ 307,944; Supplementary Fig. 1 ).
Sequencing of exons 3 and 4 of ARID5B. Ten nanograms of genomic DNA from 63 of the CEPH HapMap samples was used to amplify and sequence exons 3 and 4 of the ARID5B gene (Supplementary Table 9 ). Sequencing of the amplified product was performed using the dye-terminator chemistry (Applied Biosystems) in the St. Jude Children's Research Hospitals' Hartwell Center for Bioinformatics.
Measurement of methotrexate polyglutamate accumulation. In vivo intracellular accumulation of methotrexate polyglutamate metabolites was measured as previously described [42] [43] [44] in bone marrow leukemic lymphoblasts from 118 individuals with ALL. Bone marrow samples were obtained 42-44 h after a single treatment with high-dose methotrexate (1 g/m 2 given intravenously over 4 or 24 h) during the 'upfront window' before remission induction therapy 34, 35 .
Gene expression profiling. Total RNA was extracted (TRI Reagent, MRC) from cryopreserved mononuclear cell suspensions from bone marrow obtained from 156 individuals of European descent at the time of diagnosis of ALL. The Affymetrix HG-U133A 2.0 Array (Affymetrix Inc.), comprising more than 22,283 probe sets, was used to interrogate the expression of RNA as previously described 45, 46 . Gene expression data were analyzed by using the Affymetrix MAS5.0 algorithm.
Statistical analysis
The ancestry of children with ALL in both the discovery and validation cohorts was inferred on the basis of the approximately 200,000 SNPs with a call rate 499%. We used the genotypes of samples from the International HapMap project (phase II; 210 unrelated individuals of known ancestry) as a reference population and used STRUCTURE 47 to assess the percentage of European, African and Asian ancestry for each case. Children whose ancestry was 490% European were included in the study; however, almost identical SNP associations were observed when we used more stringent criteria (95% rather than 90%) to define European ancestry (Supplementary Table 10 ).
R 2.6.1 statistical software was used for analysis. For each SNP, logistic regression was used to compare the frequency of the B allele (for example, for genotypes AA, AB and BB, the frequency of the B allele is 0, 1 and 2) between the ALL case population and the combined control group and between the ALL case population and each of the three non-ALL control groups. A multinomial log-linear model was used to compare the allele frequencies of selected SNPs among the four ALL subtypes. Logistic regression was also used to compare allele frequencies between single ALL subtypes and all other subtypes combined (for example, B-hyperdiploid ALL versus non-B-hyperdiploid ALL; Supplementary Fig. 1 ). All odds ratios reported are allelic odds ratios unless noted otherwise. All P values are reported as two-tailed P values.
The association between SNPs in ARID5B and leukemia-cell gene expression was analyzed by multiple linear regression for each of the 22,283 probe sets on the Affymetrix HG-U133A 2.0 Array (Affymetrix Inc). The probe sets were rank-ordered by their significance in the regression model as assessed by analysis of variance (ANOVA). False discovery rates were estimated by using the q-value method. Multiple linear regression analysis was also used to compare SNP genotypes with methotrexate polyglutamate accumulation.
Data analysis overview. First, we compared the allele frequencies of 307,944 SNP genotypes in the discovery cohort of 317 individuals with ALL and the non-ALL control groups ( Supplementary Fig. 1 ). Second, SNPs whose allele frequency differed between individuals with ALL and the combined non-ALL group (P o 1.0 Â 10 À5 ), and between the ALL group and each of the three individual non-ALL groups (P o 0.01), were then compared among the four ALL subtypes. SNPs that distinguished among ALL subtypes were then tested in an independent validation cohort of 124 children of European descent with ALL. As a secondary analysis, we compared SNP genotypes only within ALL cases in the discovery cohort that distinguished among the four main ALL subtypes without considering the non-ALL controls ( Supplementary  Tables 4-7) .
